Ionis - Biotech company impresses with strong pipeline!
Reading Time: 1 minute
The biotech company specializes in the development of drugs and therapies for the treatment of rare genetic disorders. With Spiranza (spinal muscular atrophy (SMA)), Tegsedi (hereditary transthyretin amyloidosis (hATTR)), and Waylivra (Familial Chylomicronemia Syndrome (FCS)), Ionis has several approved products, while also having a well-stocked pipeline. Here, hopes rest primarily on Olezarsen, a drug that has proven promising in the treatment of Familial Chylomicronemia Syndrome, a rare, often fatal genetic disorder. Recently, positive results...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
